Abstract European LeukemiaNet defines the clinical signs and symptoms (CSSs) of polycythemia vera (PV) as progressive splenomegaly, leukocytosis, thrombocytosis, inadequate hematocrit control, and cardiovascular risk factors. In PV patients receiving hydroxyurea, CSSs indicate a phenotype with higher thrombosis risk across the standard risk categories.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniela Cilloni
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers
You are already at the latest version Background/Objectives: This study aimed to assess the unmet needs of myelodysplas-tic neoplasm (MDS) patients and their caregivers, focusing on how these needs impact quality of life (QoL) and daily functioning. MDS predominantly affects older adults. It is often complicated by severe red blood cell transfusion-dependent anemia and may require frequent hospital visits, conferring a substantial burden on patients and care-givers.
Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Ubiquitin-Conjugating Enzyme E2 O (UBE2O) and Its Therapeutic Potential in Human Leukemias and Solid Tumors
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Detection of C-KIT Mutations in Systemic Mastocytosis: How, When and Why
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 29 August 2024 / Approved: 30 August 2024 / Online: 30 August 2024 (15:44:52 CEST) Cilloni, D.; Maffeo, B.; Savi, A.; Danzero, A. C.; Bonuomo, V.; Fava, C. Detection of C-KIT Mutations in Systemic Mastocytosis: How, When and Why. Preprints 2024, 2024082240. https://doi.org/10.20944/preprints202408.2240.v1 Cilloni, D.; Maffeo, B.; Savi, A.; Danzero, A. C.; Bonuomo, V.; Fava, C.
Cerebral Vein Thrombosis and Direct Oral Anticoagulants: A Review
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 10 July 2024 / Approved: 11 July 2024 / Online: 11 July 2024 (04:52:20 CEST) Maffeo, B.; Cilloni, D. The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors. Preprints 2024, 2024070916. https://doi.org/10.20944/preprints202407.0916.v1 Maffeo, B.; Cilloni, D. The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors.
A Leukemic Target with a Thousand Faces: The Mitochondria
1. Introduction Acute myeloid leukemia (AML) is an aggressive disease that is still characterized by a dismal prognosis in a significant number of patients: the 5-year overall survival (OS) in the adult population is around 28%, but if patients over 65 are selected, OS is less than 10% [1]. Similarly, patients affected by high-risk AMLs have an OS below 20%, despite age [2,3].
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
Article Menu /ajax/scifeed/subscribe Altmetric announcement Help format_quote Cite thumb_up ... Endorse Need Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniela
Contact Daniela, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack